"Your thoughts? it shrunk all tumor in the 9 patients studied in renal...very similar to cabo...not sure why gsk is studying it for this population if cabo is already p3?"
I don't know why this drug is not a higher priority for them. You would think they would have at least tried a ph 1 in CRPC after Cabo's initial activity was reported in 2010. I have no explanation except to say that they have all the data and may know something that isn't superficially apparent to the rest of us.